Gandasegui, Javier; Onwuchekwa, Chukwuemeka; Krolewiecki, Alejandro J; Doyle, Stephen R; Pullan, Rachel L; Enbiale, Wendemagegn; Kepha, Stella; Hatherell, Hollie Ann; van Lieshout, Lisette; Cambra-Pellejà, María; +2 more... Escola, Valdemiro; Muñoz, José; (2022) Ivermectin and albendazole coadministration: opportunities for strongyloidiasis control. The Lancet. Infectious diseases, 22 (11). e341-e347. ISSN 1473-3099 DOI: https://doi.org/10.1016/S1473-3099(22)00369-3
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
Abstract
In 2020, WHO recognised the importance of strongyloidiasis alongside soil-transmitted helminths (STH) in their 2021-30 roadmap, which aspires to target Strongyloides stercoralis with preventive chemotherapy by use of ivermectin. Combination treatment with both albendazole, the primary drug used to treat STH, and ivermectin, would improve the efficiency of mass drug administration targeting both STH and S stercoralis. In this Personal View, we discuss the challenges and opportunities towards the development of an efficient control programme for strongyloidiasis, particularly if it is to run concurrently with STH control. We argue the need to define the prevalence threshold to implement preventive chemotherapy for S stercoralis, the target populations and optimal dosing schedules, and discuss the added benefits of a fixed-dose coformulation of ivermectin and albendazole. Implementation of an efficient control programme will require improvements to current diagnostics, and validation of new diagnostics, to target and monitor S stercoralis infections, and consideration of the challenges of multispecies diagnostics for S stercoralis and STH control. Finally, the evolution of ivermectin resistance represents a credible risk to control S stercoralis; we argue that genome-wide approaches, together with improved genome resources, are needed to characterise and prevent the emergence of resistance. Overcoming these challenges will help to reduce strongyloidiasis burden and enhance the feasibility of controlling it worldwide.
Item Type | Article |
---|---|
Faculty and Department | Faculty of Infectious and Tropical Diseases > Dept of Disease Control |
PubMed ID | 35850127 |
Elements ID | 181747 |
Official URL | http://dx.doi.org/10.1016/s1473-3099(22)00369-3 |
Download
Filename: Gandasegui-etal-Ivermectin-and-albendazole-co-administration.pdf
Description: This is an author accepted manuscript version of an article accepted for publication, and following peer review. Please be aware that minor differences may exist between this version and the final version if you wish to cite from it
Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
Download